HDAC9 and neoplasm: We have previously described the antitumor action of the pan-HDAC inhibitors SAHA (Vorinostat) and ITF2357 (Givinostat) in different tumor cells, outlining their action mechanisms (Carlisi et al., 2015; Celesia et al., 2022a; Zichittella et al., 2023; Celesia et al., 2023).